RBM5 and breast cancer: One cytotoxic isoform, RBM5 + 5 + 6 t, was downregulated in breast cancer cells (both primary tumors and a cell line) that have overexpressed HER2 [19], which suggested that factors in the EGFR pathway may function as upstream modulators of RBM5 function and/or expression.